Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px
Document › Details

Illumina, Inc.. (3/5/15). "Press Release: Illumina Names Albiogen as Eastern Europe Distributor. Relationship Enhances Customer Experience and Faster Turn Around Times". Moscow.

Region Region Russian Federation
Organisations Organisation Illumina Inc. (Nasdaq: ILMN)
  Group Illumina (Group)
  Organisation 2 Albiogen Ltd. (RU)
Products Product DNA sequencing system
  Product 2 DNA sequencing
Index term Index term Albiogen–Illumina: DNA sequencing technology, 201503– distribution of Illumina platforms + solutions in RU + Belarus + Kazakhstan by Albiogen
Person Person Crutchfield, Brad (Qiagen 201506–2016 SVP before Illumina + NanoString + Bio-Rad STEPPED DOWN 2016)
     


Illumina, Inc. (NASDAQ:ILMN) today announced it has extended its distribution channel through a new relationship with Albiogen Ltd., a life science distributor that specializes in next-generation sequencing (NGS), headquartered in Moscow. Albiogen will expand the reach of Illumina's array of next-generation sequencing platforms and solutions across the Russian Federation and Commonwealth of Independent States.

"We believe that our relationship with Albiogen will greatly enhance our ability to support our growing Russian customer base," said Brad Crutchfield, vice president and general manager of Europe, Middle East and Africa Commercial Operations at Illumina, "With their expertise in sequencing and extensive regional network, Albiogen is an ideal distributor to provide sales and field level support."

Effective March 1, 2015, Albiogen will distribute Illumina's applications and systems to the Russian Federation, the Republic of Belarus, and Republic of Kazakhstan. Customers will have full access to Illumina's leading-edge products and services, including the world's most comprehensive NGS systems, assays, and core consumables.

Albiogen will leverage its extensive experience in sales and marketing, knowledge in sequencing instruments, and network to deliver a faster turnaround time, improved customer experience and user-friendly ordering process.


About Illumina, Inc.

Illumina is transforming human health as the global leader in sequencing and array-based technologies. The company serves customers in a broad range of markets, enabling the adoption of genomic solutions in research and clinical settings. To learn how Illumina is unlocking the power of the genome, visit www.illumina.com and follow @illumina.


Forward-Looking Statements

This release may contain forward-looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.


Investors:
Rebecca Chambers
858-255-5243
rchambers@illumina.com

Media:
Jennifer Temple
858-882-6822
pr@illumina.com

   
Record changed: 2019-04-26

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Illumina (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px




» top